Actively Recruiting
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
Led by Christoffer Johansen · Updated on 2025-07-29
920
Participants Needed
7
Research Sites
217 weeks
Total Duration
On this page
Sponsors
C
Christoffer Johansen
Lead Sponsor
R
Rigshospitalet, Denmark
Collaborating Sponsor
AI-Summary
What this Trial Is About
Patients diagnosed with hematologic cancer are at substantial risk of dying, as 5-year survival among patients with acute myeloid leukemia is 20 % and only every second patient treated for incurable myeloma lives 5 years after date of diagnosis. Nevertheless, many overestimate their prognosis, and value of therapy. Patients with hematological cancers frequently have poor end of life outcomes, such as high treatment activity close to death, where clinical effects are doubtful, and low utilization of palliative care. Prognostic awareness and end of life (EOL) issues have urgency in the communication between patients, their caregiving relatives, and clinicians, in order to avoid futile treatments and suffering at EOL. Inspired by advanced care planning, the investigators developed the concept "Advance Consultations Concerning participants Life and Treatment" (ACT) in collaboration with a group consisting of hematologists, nurses, patients, and caregivers. The ACT concept consists of an 8-hour training day for clinicians, clinical tools, system changes, and preparation material for patients and caregivers prior to the consultation. ACT involves patients and caregivers earlier in preparation for life with chronic progressive disease and EOL-decisions, through an intervention based on compassionate communication and early planning of EOL-care. The aim of the study is to investigate the effect of the intervention on use of chemotherapy and quality of EOL-care in patients with hematological malignancy. Based on the results of the completed pilot study, the investigators are planning a nationwide 2-arm cluster randomized controlled trial where 40 physicians and 80 nurses across seven different hematological departments are randomized to either usual care or ACT training and completing ACT conversations. The investigators expect to include a total of 400 patients and their family caregivers. It is hypothesized that the ACT intervention will decrease use of futile chemotherapy, prepare patients and caregivers for difficult end-of-life-decisions, and improve quality of end-of-life care in hematology.
CONDITIONS
Official Title
Compassionate Communication and Advance Care Planning to Improve End of Life Care in Treatment of Hematological Disease (ACT)
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Be at least 18 years old
- Diagnosed with high-risk myelodysplastic syndrome or myelodysplastic syndrome with overlap of myeloproliferative neoplasms
- Diagnosed with acute myeloid leukemia and aged 80 or older, or in palliative treatment, or experiencing relapse
- Diagnosed with lymphoma and aged 80 or older, or experiencing relapse, refractory disease, or in palliative treatment
- Diagnosed with multiple myeloma and aged 80 or older, or relapsed, or refractory
- Have limited treatment options
- Provide informed consent
- Have sufficient Danish skills to complete intervention sessions and data collection
- Have an informal caregiver who is at least 18 years old, can accompany to appointments, provides informed consent, and has sufficient Danish skills
- Physicians specialized in hematology treating the above patients and working at the same department for the entire intervention period
- Nurses treating the above patients and working at the same department for the entire intervention period
You will not qualify if you...
- Patient or caregiver suffering from a severe psychiatric disorder
- Physicians or nurses who do not meet the inclusion criteria
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 7 locations
1
Aalborg Universitetshospital
Aalborg, Denmark, 9100
Actively Recruiting
2
Aarhus Universitetshospital
Aarhus, Denmark, 8200
Actively Recruiting
3
Sydvestjysk sygehus - Esbjerg
Esbjerg, Denmark, 6700
Actively Recruiting
4
Regionshospitalet Gødstrup
Herning, Denmark, 7400
Actively Recruiting
5
Odense Universitetshospital
Odense, Denmark, 5000
Actively Recruiting
6
Sjællands universitetshospital Roskilde
Roskilde, Denmark, 4000
Actively Recruiting
7
Lillebælt syge - Vejle Sygehus
Vejle, Denmark, 7100
Actively Recruiting
Research Team
C
Cæcilie Borregaard Myrhøj, MScN
CONTACT
A
Annika von Heymann, PhD
CONTACT
How is the study designed?
Study Type
INTERVENTIONAL
Masking
NONE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
SUPPORTIVE_CARE
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here